💊💉 #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 10. Date of revision of the text on 20 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history
Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)

Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by SANOFI

💊💉 #aflibercept
SmPC for ZALTRAP 25 mg/ml concentrate for solution for infusion has been updated with changes to sections 2. Qualitative and quantitative composition; 4.6 Fertility, pregnancy and lactation; 5.2 Pharmacokinetic properties; 6.5 Nature and contents of container; 10. Date of revision of the text on 01 December 2023.
🌐 https://www.medicines.org.uk/emc/product/2971/smpc
Change log: https://www.medicines.org.uk/emc/product/2971/smpc/history
Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc)

Zaltrap 25mg/ml concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by SANOFI

Researchers report one drug more effective in treating wet age-related macular degeneration

Researchers say the drug aflibercept performed better in a clinical trial than bevacizumab in helping wean people off treatments for wet age-related macular degeneration

Medical News Today